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Abstract
Background: Alzheimer disease (AD) is clinically characterized by progressive memory loss,
impairments in behavior, language and visual-spatial skills and ultimately, death. Epidemiological data
reporting the predisposition of women to AD has led to a number of lines of evidence suggesting
that age-related changes in hormones of the hypothalamic-pituitary-gonadal (HPG) axis following
reproductive senescence, may contribute to the etiology of AD. Recent studies from our group
and others have reported not only increases in circulating gonadotropins, namely luteinizing
hormone (LH) in individuals with AD compared with control individuals, but also significant
elevations of LH in vulnerable neuronal populations in individuals with AD compared to control
cases as well as the highest density of gonadotropin receptors in the brain are found within the
hippocampus, a region devastated in AD. However, while LH is higher in AD patients, the
downstream consequences of this are incompletely understood. To begin to examine this issue,
here, we examined the expression levels of steroidogenic acute regulatory (StAR) protein, which
regulates the first key event in steroidogenesis, namely, the transport of cholesterol into the
mitochondria, and is regulated by LH through the cyclic AMP second messenger pathway, in AD
and control brain tissue.
Results: Our data revealed that StAR protein was markedly increased in both the cytoplasm of
hippocampal pyramidal neurons as well as in the cytoplasm of other non-neuronal cell types from
AD brains when compared with age-matched controls. Importantly, and suggestive of a direct
mechanistic link, StAR protein expression in AD brains colocalized with LH receptor expression.
Conclusion: Therefore, our findings suggest that LH is not only able to bind to its receptor and
induce potentially pathogenic signaling in AD, but also that steroidogenic pathways regulated by LH
may play a role in AD.
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Background
Alzheimer disease (AD), the leading cause of senile
dementia, is characterized by selective neuronal degener-
ation affecting the hippocampus and to a lesser extent
other cortical brain regions resulting in progressive mem-
ory loss, impairments in behavior, language and visual-
spatial skills and ultimately, death [1]. The etiologic
events that lead to the neuronal loss and dysfunction seen
in AD are not well understood; however, there are many
lines of evidence that suggest the sex steroids, estrogen
and testosterone, may play an important role in the
pathogenesis of AD. Epidemiological studies exploring
gender differences in AD have resulted in conflicting data,
yet most studies support the higher prevalence [2-5] and
incidence [6] of AD in women. It is our hypothesis that
hormones of the hypothalamic-pituitary-gonadal (HPG)
axis, especially age-related increases in gonadotropins,
play a key role in AD pathogenesis [7].
There is mounting evidence that supports a role for gona-
dotropins, and particularly luteinizing hormone (LH), in
AD pathogenesis beginning with the finding of a two-fold
increase in circulating gonadotropins in individuals with
AD compared with age-matched control individuals [8,9].
Significant elevations of LH were also found in vulnerable
neuronal populations in individuals with AD compared
to aged control cases [10]. Furthermore, LH has been
shown to alter amyloid β protein precursor (AβPP)
processing toward the amyloidogenic pathway [11], as
well as lead to cognitive decline in LHβ-transgenic mice
[12] that exhibit elevated LH levels and increased estradiol
and testosterone levels when compared to non-transgenic
littermates [13]. Finally, decreases in serum LH levels by
leuprolide acetate (a potent gonadotropin-lowering
agent) administration have been associated with
decreases in amyloid plaque burden and subsequent
increases in cognition in AβPP transgenic mice [12].
While evidence for the role of LH in the pathogenesis of
AD is increasing, the mechanisms by which LH contrib-
utes to neuronal dysfunction or death within the course of
the disease remains to be elucidated. In fact, although it
has been well documented that neurons in various
regions of the central nervous system synthesize sex ster-
oids (for review see [14]) that are believed to be important
for complex neuronal functions (for review see [15]), little
is currently known about the etiology or effects of gona-
dotropins, which regulate the synthesis and secretion of
sex steroids (for review see [16]), on the hippocampus.
In contrast to the consequences of LH binding to its recep-
tor in the hippocampus, the signaling cascade initiated
upon LH binding to its receptor on gonadal tissues is well
documented (for review see [17]). Upon binding to its
receptor, LH initiates the activation of membrane-associ-
ated adenylyl cyclase, causing an elevation of intracellular
cAMP [18], which serves as a second messenger for the
upregulation of the steroidogenic acute regulatory protein
(StAR) primarily through the protein kinase A (PKA)
pathway [17,19-21]. StAR transports cholesterol to the
inner mitochondrial membrane [22] where it is converted
to pregnenolone by the cytochrome P-450 enzyme com-
plex, which represents the rate limiting step in steroido-
genesis. The presence of steroidogenic enzymes within the
brain, such as aromatase, which is the enzyme involved in
the last step in the synthesis of estrogens as it converts tes-
tosterone to estrogen, was described over thirty years ago
[23], although it has only recently been widely accepted
that aromatase is expressed in both neurons and glial cells
in the hippocampus as shown at the mRNA level [24] and
protein level [25-27]. Like aromatase, while the presence
of StAR in the brain has been documented for sometime
[28], it has only recently been shown to be expressed spe-
cifically in pyramidal neurons, granule cells of the dentate
gyrus, interneurons and glial cells [29].
In this study, we found an increase in StAR in AD hippoc-
ampal neurons as well as other non-neuronal cells com-
pared to aged matched controls by immunocytochemical
methods. Furthermore, we found that StAR colocalizes to
neurons with LH receptor, which is expressed throughout
the hippocampus [30] and is known to initiate a signaling
cascade leading to increased StAR expression when bound
by its ligand [17,19-21]. This finding is suggestive of a
direct mechanistic link by providing further support that
LH is indeed able to bind to its receptor and induce poten-
tially pathogenic signaling in AD, and also that steroidog-
enic pathways regulated by LH may play a role in AD.
Results
StAR protein was markedly increased in both the cyto-
plasm of hippocampal pyramidal neurons as well as in
the cytoplasm of other cell types, such as astrocytes, from
sixteen AD brains when compared with twelve age-
matched controls (Fig. 1). Furthermore, while StAR was
predominantly found in the cytoplasm, it also localized to
neurofibrillary tangles, neuropil threads and dystrophic
neurites (Fig. 1). No significant StAR was noted in the cer-
ebral vasculature. To confirm the specificity of StAR
immunocytochemistry, several control experiments were
performed in parallel. Absorption of StAR antibody with
excess immunizing peptide was shown to appreciably
decrease immunostaining (Fig. 2), and omission of pri-
mary antibody resulted in no apparent staining.
Colocalization experiments using adjacent AD hippocam-
pal serial sections were performed in order to determine if
cells expressing StAR protein also expressed the human
LH receptor. StAR colocalized with LH receptor in both
pyramidal neurons (Fig. 3) as well as in other cells types
(data not shown) suggesting that LH, which is known toMolecular Neurodegeneration 2006, 1:14 http://www.molecularneurodegeneration.com/content/1/1/14
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be increased in AD [10], is in fact able to bind to its recep-
tor and initiate canonical signaling cascades in the hip-
pocampus despite the non-gonadal nature of the tissue. It
should be noted that follicle-stimulating hormone (FSH)
and adrenocorticotropic hormone (ACTH) are also
known to increase StAR expression ([31] and [32], respec-
tively); however, we did not include the receptors for
these hormones in this colocalization study as the FSH
receptor has not been reported in the brain and ACTH is
decreased in AD [33,34].
Discussion
In this study, we demonstrate increased levels of StAR pro-
tein in vulnerable neurons as well as in other cell types in
individuals with AD when compared to the same cellular
populations in normal, aged-matched individuals (Fig.
1). The expression of StAR in different hippocampal cell
types in this study mimics recent findings in which StAR
localized to not only pyramidal neurons, but also to gran-
ule cells of the dentate gyrus, interneurons and glial cells
in marmosets and rats [29]. We also demonstrate that
StAR colocalizes to neurons expressing LH receptor as
demonstrated on adjacent serial sections of AD hippoc-
ampal tissue (Fig. 2). Considering that LH is significantly
elevated in vulnerable neuronal populations in individu-
als with AD [10] and that the highest LH receptor expres-
sion in the brain is in the hippocampus [30], the
colocalization of StAR with LH receptor is highly sugges-
tive of a mechanistic link. Data from this study not only
suggests that LH is able to bind to its receptor and induce
signaling cascades in non-gonadal tissue, but also that the
steroidogenic consequences of increased LH binding may
play a role in AD pathogenesis. With this in mind, it is
important to note that the long held notion of the patho-
genic effects of decreased sex steroid levels, namely estro-
gen, on the brain after reproductive senescence is not
consistently reflected in studies measuring sex steroid lev-
els in AD compared to age-matched controls. For exam-
ple, only two of nine recent observational studies
comparing estrogen levels in women with AD with con-
trols reported lower estrogen levels in AD [35,36], with
two studies reporting increased estrogen levels in AD
[37,38] and five reporting no significant differences
between AD and controls [39-43]. The variability in the
results of these studies is thought to be caused in part by
the sensitivity of the assay used, as studies that used less
sensitive assays reported higher total estrogen levels [38]
resulting in an overemphasis of the impact of low estro-
gen levels on the study. Therefore, potentially elevated sex
steroid levels resulting from increased StAR expression in
The immunolocalization of StAR Figure 1
The immunolocalization of StAR. Immunocytochemical localization of StAR in AD-affected individuals is increased in pyramidal 
hippocampal neurons as well as in astrocytes (Panel A) in comparison to age-matched control brains (Panel B). Scale bar for 
panels A and B = 50 μm. Scale bar within the inset in Panel A = 25 μm.Molecular Neurodegeneration 2006, 1:14 http://www.molecularneurodegeneration.com/content/1/1/14
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AD demonstrated in this study is not necessarily contra-
dictory to epidemiological studies regarding sex steroid
levels AD.
While a consensus on sex steroid levels in AD remains elu-
sive, studies involving the role of gonadotropins, and in
particular the role LH, in AD pathogenesis support
increases in gonadotropin-induced steroidogenesis in the
hippocampus. Epidemiological studies concerning gen-
der differences in AD support the higher prevalence [2-5]
and incidence [6] of AD in women. This has led to a
number of lines of evidence suggesting that age-related
changes in hormones of the HPG axis following reproduc-
tive senescence, may contribute to the etiology of AD. Due
to the ineffectiveness of hormone replacement therapy in
the treatment of AD [44], it is our hypothesis that age-
related changes to gonadotropin levels, namely LH, con-
tribute to AD pathogenesis. The initial finding of a two-
fold increase in circulating gonadotropins in individuals
with AD [8,9] was further supported when significant ele-
vations of LH were also found in vulnerable neuronal
populations in individuals with AD compared to aged
control cases [10]. While this increase in serum LH in AD
would not be expected to result in increased sex steroid
production in the gonads due to the loss of function after
reproductive senescence, increased neuronal LH in AD
would likely induce steroidogenesis in functioning neu-
rons. In support of this notion, reported decreases in ster-
oidogenic enzyme expression, including StAR, in the post-
menopausal ovary when compared to the premenopausal
ovary [45] are in stark contrast to the increased levels of
StAR reported in this study.
LH has also been linked mechanistically to AD as evi-
denced by the effect of LH on AβPP processing toward the
amyloidogenic pathway as evidenced by increased secre-
tion and insolubility of Aβ, decreased AβPP-α secretion,
and increased AβPP-C99 levels [11]. This same study also
reported a 3.5-fold and a 1.5-fold reduction in total brain
Aβ1–42 and Aβ1–40 concentrations, respectively, in
C57Bl/6J mice treated with leuprolide acetate, a potent
gonadotropin-releasing hormone agonist shown to effec-
tively lower LH serum levels [11]. Decreases in serum LH
levels by leuprolide acetate administration have also been
associated with decreases in amyloid plaque burden and
subsequent increases in cognition in AβPP transgenic
mice [12]. Even more importantly, LHβ-transgenic mice
that exhibit elevated LH levels well as increased estradiol
Absorption verifies the specificity of antibody binding Figure 2
Absorption verifies the specificity of antibody binding. Staining in the hippocampus with StAR in AD (Panel A) is decreased by 
absorption with the immunizing peptide (Panel B). Scale bar = 50 μm.Molecular Neurodegeneration 2006, 1:14 http://www.molecularneurodegeneration.com/content/1/1/14
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and testosterone levels [13] showed cognitive deficits spe-
cifically related to learning and memory when compared
to non-transgenic littermates [12].
Conclusion
In conclusion, we have shown that StAR is upregulated in
both hippocampal pyramidal neurons and non-neuronal
cell types in AD, and that StAR expression colocalizes with
LH receptor expression in this same cellular population.
This finding is suggestive of a direct mechanistic link by
suggesting that LH is able to bind to its receptor and
induce potentially pathogenic signaling despite the non-
gonadal nature of the hippocampus, and also that ster-
oidogenic pathways regulated by LH may play a role in
AD (Fig. 4). This study provides the first connection
between gonadotropins and sex steroids in the brain and
offers insight into the mechanism of LH-induced patho-
genesis in AD.
Materials and methods
Tissue
Hippocampal or cortical tissue samples were obtained
post mortem from patients (n = 16, ages 67–96 years,
mean = 84.7 years) with clinically and histopathologically
confirmed AD, as well as from aged-matched controls (n
= 12, ages 66–86 years, mean = 76.4 years) with similar
post mortem intervals (AD: 5.5–25 h, mean = 9.6 h; con-
trols: 6–27 h, mean = 13.4 h). All cases were categorized
based on clinical and pathological criteria established by
CERAD and NIA consensus panel [46]. From the clinical
reports available to us, we found no obvious differences in
agonal status or other potential confounders between the
groups. Tissue was fixed in methacarn (methanol: chloro-
form: acetic acid; 6: 3: 1 v/v/v) at 4°C overnight. Follow-
ing fixation, tissue was dehydrated through ascending
ethanol, embedded in paraffin, and 6-μm sections were
placed on silane-coated slides (Sigma, St. Louis, MO,
USA).
Immunocytochemistry
Tissue sections were deparaffinized in xylene, hydrated
through descending ethanol, and endogenous peroxidase
activity was quenched by thirty minute incubation in 3%
hydrogen peroxide in methanol. Non-specific binding
sites were blocked with thirty minute incubation in 10%
normal goat serum. Tissue sections were immunostained
with a rabbit polyclonal antibody to StAR (1:100) [47]
and/or a rabbit polyclonal antibody to the human lutein-
izing hormone receptor (1:50) (GeneTex, Inc., TX, USA)
followed by the peroxidase-antiperoxidase method with
3-3'-diaminobenzidine as co-substrate as previously
described. Sections were also immunostained with a
Immunocytochemical analysis of the distribution of StAR and hLH/CG receptor Figure 3
Immunocytochemical analysis of the distribution of StAR and hLH/CG receptor. Adjacent serial hippocampal sections of an AD 
patient show overlap between StAR immunolocalization (Panel A) and hLH/CG receptor immunolocalization (Panel B). 
Arrows point to neurons included in both hippocampal sections that show positive immunoreactivity for StAR and LH recep-
tor. Asterisk denotes landmark vessel. Scale bar = 50 μm.Molecular Neurodegeneration 2006, 1:14 http://www.molecularneurodegeneration.com/content/1/1/14
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monoclonal mouse antibody, AT8 (1:1000), which recog-
nizes phosphorylated tau (Ser202/Thr205) (Pierce, Rock-
ford, IL) to identify the location of neuronal pathological
structures. Control experiments included omission of pri-
mary antisera. Absorption experiments were performed to
verify the specificity of antibody binding. StAR antigen
[47] (20 mg), was linked to Aminolink Plus Coupling Gel
(Pierce, Rockford, IL) following manufacturers directions,
and incubated together with diluted antibody for 16
hours at 4°C on a rotator. After centrifugation, the
"adsorbed" antibody solution was used for immunocyto-
chemistry. For this experiment, the "unadsorbed" anti-
body was prepared by incubating diluted StAR antibody
with the coupling gel only.
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